Getinge overview An expanding MedicalTechnology group with focus

Getinge overview An expanding Medical-Technology group with focus on comprehensive solutions for infection control, surgical systems and care of elderly and disabled people Customers Net Sales Associates Manufacturing Distribution (ex Jostra and LSS) Acute care Long term care Industry / Laboratories 8. 6 billion SEK 5 600 18 production units in 9 countries 70 sales companies in 25 countries Distributors in 100 countries

Business Scope Business Areas Infection Control Extended Care Surgical Systems 40% 31 % 29 % Industry Acute Care I 0 % 60 % Long Term Care 30 % Customer Segments (ex Jostra and LSS)

Group objectives & focus 3

Getinge Group Objectives Strategic n To develop world leading positions in prioritized niches of the health care industry 4

Strong Global Positions Business unit Position Market shares BA Infection Control Sterilization Disinfection # 1 24 % 27 % BA Surgical Systems Surgical Tables Surgical Lights Ventilators Cardiopulmonary Ceiling Service Units Anaesthesia # 1 #1 # 3 #3 40 % 38 % 22 % 15 % 6% BA Extended Care Hygiene Systems Patient Handling Wound Care # 1 # 4 60 % 40 % 5%

Getinge Group Objectives Strategic n To develop world leading positions in prioritized niches of the health care industry Financial n To increase profit before tax with an average of I 5% per annum n Internally generated cash flow to sustain an external growth rate of I 0% per annum 6

The Getinge Group 10000 9000 8000 7000 6000 5000 4000 3000 2000 1000 800 600 400 200 0 CAGR 24 % 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 Invoiced sales Profit before tax 7

The Getinge Group - Focus & Development Infection Control Extended Care Surgical Systems Improved Operating Performance Organic Growth External Growth

Review of Business Areas 9

Infection Control Create a customer focused group from a number of companies acquired over the last 10 years

INFECTION CONTROL 1990 - 2000 Growth through acquisition 2000 - 2002 Restructuring - Improve production structure - Organisational focus - Brand identity 2003 Business development - Organic growth - Product development - Integrated solutions - Logistics / distribution - Service provider concept

Infection Control Orders received MSEK 2003 2002 Q 3 Western Europe 386 USA and Canada Asia and Australia per market Rest of the world Business area tot. Adj curr 2003 2002 Adj curr flucs & acqs 9 mon flucs & acqs 358 11% 1 134 2% 331 313 30% 863 1 062 3% 107 99 9% 292 278 9% 66 59 13% 192 142 38% 890 829 18% 2 481 2 616 5%

Infection Control Results MSEK Net sales Gross margin % Operating cost Operating profit Operating margin % 2003 2002 Q 3 9 mon FY 745 2, 302 2, 288 3, 359 37. 7% 34. 3% 39. 2% 35. 0% 36. 2% -199 -215 -630 -679 -910 82 40 273 121 306 11. 0% 5. 4% 11. 9% 5. 3% 9. 1%

Extended Care Focus on growth from a solid platform through product innovation, market penetration and geographical expansion

HIGHLIGHTS 2003 GROWTH n n n Market penetration Strong product pipeline Geographical expansion COMPETITIVENESS n n n Global sourcing Improved production structure Improved logistics

Extended Care Orders received MSEK 2003 2002 Q 3 Western Europe 380 USA and Canada per market Asia and Australia Rest of the world Business area tot. Adj curr 2003 2002 Adj curr flucs & acqs 9 mon flucs & acqs 406 -1% 1 235 1 218 6% 199 248 -7% 577 734 -5% 19 20 -1% 56 56 7% 5 6 -2% 13 20 -34% 603 680 -3% 1 881 2 028 2%

Extended Care Results MSEK Net sales Gross margin % Operating cost Operating profit Operating margin % 2003 2002 Q 3 9 mon FY 583 640 1, 798 1, 981 2, 720 47. 2% 50. 0% 47. 8% 50. 4% 51. 0% -181 -223 -595 -682 -900 95 98 265 317 488 16. 2% 15. 3% 14. 7% 16. 0% 17. 9%

Surgical Systems Create a global leader in the field of Surgical workstations as a platform for further growth in the surgical systems market

SURGICAL WORKSTATIONS n Growth opportunities u n Japan and USA Product development u AWIGS / VIWAS u New Pendant generation u New Light technology n Cross selling n Heraeus integration

OPERATING THEATRE

EXTERNAL GROWTH Surgical Systems Radiology Patient monitoring Life Support Disposables Surgical instruments Ancillary Equipment

Acquisition of Jostra - business unit Cardiopulmonary 22

Jostra in brief n Sales approx 90 M EUR in 2002 n Associates ~ 600 n Sales in 100 countries, own sales companies in: DE, FR, IT, JP, CA, ES, GB, NL, SE, CN, HK n Production: Germany (2 sites), Sweden and Denmark n Products: Heart-lung machines, Oxygenators, Centrifugal pumps, related Disposables, Minimal Invasive on-pump Equipment n Excellent technology and product pipeline, 55 issued patents n Good track record of organic growth 10% +

Jostra Integration and Restructuring n New management team from 1 st August 2003 n Integration of Jostra’s sales and marketing organisation with that of Surgical Systems n Consolidation of Jostra production structure from 4 to 2 sites n Reinforce sales and marketing organisation to drive market penetration in Europe and emerging markets n Focus the R&D pipeline to deliver new technologies in a speedy and timely manner

Jostra Acquisition Financials n The target is to improve Jostra’s EBIT margin to 12 - 15% within 3 years after goodwill amortization n Contribution to group earnings in 2003 will be slightly negative to neutral n Contribution to group pre-tax profit including goodwill amortization and related financial charges will be in the range of EUR 5 - 6 million in 2004

Acquisition of Siemens LSS - business unit Critical Care 26

Key Data of LSS Life Support Systems (LSS) LSS is one of the world’s leading providers of ventilation and anaesthesia products in the critical care equipment market In 2002/03, LSS have projected revenues of around 205 MEUR The worldwide ventilation and anaesthesia hospital markets account for approx 550 MEUR annual sales volume each, with an expected annual growth of approx. 5% p. a. LSS-Ventilation LSS-Anaesthesia Sales of 175 MEUR Sales of 30 MEUR Global market shares 27% Global market shares 6%

Total LSS Sales in 2002 by Region

Financials LSS will contribute with 10 - 12 MEUR to pretax profit in fiscal 2004 LSS will contribute with 17 - 20 MEUR to pretax profit in fiscal 2005 Operating margins after goodwill depreciation is targeted at 15% longterm

Surgical Systems Orders received MSEK 2003 2002 per market Q 3 Western Europe 446 USA and Canada Asia and Australia Rest of the world Business area tot. Adj curr 2003 2002 Adj curr flucs & acqs 9 mon flucs & acqs 387 -12% 1 234 1 054 3% 136 154 -23% 366 381 4% 122 75 33% 354 284 15% 66 32 51% 128 129 -20% 770 648 -6% 2 082 1 848 3%

Surgical Systems Results MSEK Net sales Gross margin % Operating cost Operating profit Operating margin % 2003 2002 Q 3 9 mon FY 754 660 2, 101 1, 743 2, 521 49. 7% 50. 5% 48. 7% 49. 1% 47. 6% -296 -283 -782 -694 -946 78 51 241 162 255 10. 4% 7. 7% 11. 4% 9. 3% 10. 1%

Results Q 3 2003 32

Getinge AB Results MSEK 2003 2002 Q 3 2 091 2 054 EBITDA 361 Operating profit Net sales Operating margin Profit before tax Change 2002 9 mon 2% 6 231 6 041 3% 8 640 289 25% 1 080 894 21% 1 438 255 188 36% 779 601 30% 1 050 12, 2% 9, 2% 12, 5% 9, 9% 216 146 664 471 48% Change 2002 2003 FY 12, 1% 41% 876

Getinge AB Balance sheets MSEK Assets 2003 -09 -30 2002 -12 -31 Fixed assets 4, 751 4, 577 4, 564 Current assets 4, 735 4, 822 4, 852 Total assets 9, 486 9, 399 9, 416 Shareholders' equity 3, 230 2, 893 3, 158 Provisions 1, 955 2, 084 1, 943 Long-term liabilities 1, 383 2, 835 2, 441 Current liabilities 2, 918 1, 587 1, 874 Total Equity & Liabilities 9, 486 9, 399 9, 416 1. 01 1. 32 1. 07 34. 1% 30. 8% 33. 5% Shareholders' equity & liabilities Key figures Net debt/equity, multiple Equity/Assets ratio, per cent

Getinge AB Key figures Operating Cash Flow, MSEK Net debt, MSEK Equity / Assets ratio, % Net debt / Equity ratio, multiple Interest cover, multiple Q 3 495 Q 3 365 9 mon FY 1, 424 1, 107 1, 784 3, 259 3, 817 3, 376 34. 0% 30. 8% 33. 5% 1. 01 1. 32 1. 07 7. 7 5. 3 5. 9